Medical devices, healthcare technology and the business of care
510(k) clearance · K262432

CorDx Tyfast Flu A/B & COVID-19 At Home Multiplex Rapid Test; CorDx Tyfast Flu A/B & COVID-19 Multiplex Rapid Test

CorDx, Inc. · Decision date Oct 14, 2026

MEDTECHLEDGER EXPLANATIONK262432

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on 2026-10-14 for K262432, submitted by CorDx, Inc. of Alpharetta, Georgia, under product code SCA and the Microbiology specialty. The listed device names are the CorDx Tyfast Flu A/B & COVID-19 At Home Multiplex Rapid Test and the CorDx Tyfast Flu A/B & COVID-19 Multiplex Rapid Test, classified as a multi-analyte respiratory virus antigen detection test. The application was received 07/16/2026 and reviewed as a traditional 510(k) without third-party review, combination product status or an authorized predetermined change control plan.

A separate CLIA database entry, document CR260530 tied to K262432, lists both named tests with anterior nasal swab sampling as waived for SARS-CoV-2 and other respiratory viruses in virology, effective 10/20/2026. That waiver record is distinct from the 510(k) clearance itself. The source material does not include the decision summary, so the specific components, changed items, analytical or clinical performance data and any labeling limitations remain unknown and are not characterized here.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Microbiology
Decision date
Oct 14, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K262432
Regulatory pathway
510(k) premarket notification
Applicant
CorDx, Inc.
Product code
SCA
Decision code
SESE
Decision date
Oct 14, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Multi-Analyte Respiratory Virus Antigen Detection Test.

Applicant
CorDx, Inc.
Product code
SCA
FDA device class
2

FDA decision timeline

  1. K262432 received

    Application receipt date recorded by FDA.

  2. K262432 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

CorDx, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Alpharetta, GA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records